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ScienceDirectThe 21st century has seen the licensure of new anti-infective
vaccines that have demonstrated their benefit for both
individual and population (herd) protection. Despite this there
are still many human pathogens for which no vaccine is
available. As we learn more about these pathogens, and as
technologies advance, more opportunities for vaccine
development have become available. This review will address
these advances and highlight the paradigm shift from vaccines
that are used on a population basis, to others which will have an
individual benefit, if successfully licensed, but are not expected
to have widespread population based use. The development of
the latter vaccines has resulted in a paradigm shift toward
vaccinating individuals at specific risk for infection from
bacteria such as Staphylococcus aureus or Clostridium difficile,
which are members of normal human flora but can cause
severe disease under certain circumstances. Increasing levels
of antibiotic resistance in such bacteria such as S. aureus have
also driven the urgency for the identification of alternative
methods of protection that do not rely on treatment or
prophylaxis with antibiotics.
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Introduction
Mass vaccination campaigns deployed in the twentieth
century had the potential to eradicate, or significantly
curtail, major childhood infectious diseases including
measles, mumps, rubella, varicella, smallpox, diphtheria,
hepatitis, polio, influenza, pertussis and tetanus. Provided
that these vaccines are widely employed, both the indi-
vidual and the population can be protected from disease,
through induction of herd immunity. Herd immunity
requires vaccination rates to be high; when numbersCurrent Opinion in Microbiology 2015, 27:96–102 decline, diseases can re-emerge, as has been observed with
recent measles outbreaks in the US. In eight US states, the
measles/mumps/rubella (MMR) vaccination rate for chil-
dren entering kindergarten had fallen to <90% for the
2013–2014 school year [1], placing the broader population
at risk. Measles cases in the US went from a median of
60 cases a year (2000–2010) to over 600 cases in 2014 [2].
The majority of these cases were in unimmunized individ-
uals; 16% of cases were reported in children under one year
of age, too young to be routinely immunized with MMR
[2,3]. This current example illustrates that high immuni-
zation coverage is important not only for the protection of
the broader immunized population but also for the protec-
tion of vulnerable populations who are either too young to
be effectively vaccinated or have medical conditions that
contraindicate vaccination. Though this is a critical con-
cept for vaccines that protect from most infectious diseases,
there are also vaccines in development that will have
individual impact, but will not be used in mass vaccination
campaigns. For healthcare associated pathogens, such as
Clostridium difficile and Staphylococcus aureus, patients who
are at risk of infection can be vaccinated, circumventing the
need for mass vaccination.
This review will trace the history of anti-infective vac-
cines in the 21st century, from recently licensed vaccines,
to vaccines in late state development and then to vaccines
that are either early in development or for which no
technical path forward has been established.
Vaccine breakthroughs this century
The end of the twentieth and dawn of the 21st century saw
the introduction of polysaccharide conjugate vaccines for
the prevention of childhood meningitis and invasive dis-
eases caused by Haemophilus influenzae type b (Hib), Strep-
tococcus pneumoniae and Neisseria meningitidis. All of these
pathogens evade the human innate immune system by
cloaking themselves in polysaccharide capsules. Polysac-
charides alone are poorly immunogenic in the very young
[4]. With the discovery that conjugation of polysaccharides
to proteins, usually detoxified bacterial toxins, could in-
duce a long lasting immune response in infants and tod-
dlers, immunogenic and protective vaccines to these
pathogens could be developed [4]. Prior to the introduction
of prophylactic Hib vaccines, disease rates in US children
under 5 years of age were over 37 cases per 100 000 popu-
lation (100k/p) in 1989; however, within only 2 years after
Hib vaccine implementation the disease burden hadwww.sciencedirect.com
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success was observed after the introduction of pneumo-
coccal conjugate vaccines, where the overall pneumococcal
disease rates of 98.7 per 100k/p in children under 5 years of
age were reduced to <23.6 per 100k/p 7 years after imple-
mentation of the vaccine into the US infant vaccination
schedule [6]. Significantly, coverage of pneumococcal ser-
otypes contained in the vaccine approached 100% [7]. In
addition to this enormous positive impact on public health,
an additional and unanticipated major benefit of vaccine
introduction in infants and toddlers was observed in un-
vaccinated adults where invasive pneumococcal disease
cases dropped by >28% within 4 years of licensing the
pneumococcal conjugate vaccine by the induction of herd
immunity [8,9].
While the majority of Hib disease is caused by a single
capsule type there are over 30 disease-causing serotypes
of pneumococci. The first pneumococcal conjugate vac-
cine covered 82% of disease-causing serotypes in children
<5 years [6]. After introduction, there was an increase in
disease caused by some serotypes not included in the
heptavalent vaccine (PCV-7, Pfizer) [6,10], therefore 10-
valent and 13-valent vaccines were developed that cov-
ered 65–85% and 80–90% of the remaining disease,
respectively [11]. Pneumococcal conjugate vaccines have
also recently been demonstrated to be highly effective at
inducing long lasting immunity [12–14] and efficacy
against invasive disease and community acquired pneu-
monia in adults [15]. Vaccines with expanded serotype
coverage are now in development to protect against
additional serotypes [16,17].
Like pneumococci, N. meningitidis bacteria are classified
by their polysaccharide capsules. Of the 12 described
capsules, 5 (A, B, C, Y and W) cause the majority of
disease [18]. The first polysaccharide conjugate vaccines
were developed to prevent serogroup C disease in chil-
dren [19]. Mass vaccination campaigns in the UK saw
disease rates decline from 0.55 per 100k/p to 0.02 per
100k/p [20] and as with pneumococcal conjugate vaccines
herd immunity was observed. Through prevention of
disease and asymptomatic carriage in adolescents and
young adults, who are the primary reservoir for this
pathogen, protection was afforded to babies and toddlers
[21]. With the success of monovalent serogroup C vac-
cines, tetravalent-polysaccharide vaccines were devel-
oped to protect against serogroups A, C, Y and W. A
polysaccharide conjugate approach was not feasible for
serogroup B (MnB) due to the fact that the serogroup B
capsular polysaccharide is composed of polysaccharide
sialic acid structures that are similar to those observed on
human neuronal cells, and thus such vaccine candidates
were poorly immunogenic [22]. Antigenic plasticity and
differential expression of many meningococcal surface
proteins further complicated the development of an
effective MnB vaccine [23,24]. In the last two yearswww.sciencedirect.com the significant medical need of protecting against MnB
has now been addressed, with the recent licensure of two
vaccines. Both vaccines share a component, a factor H
binding protein (fHBP) which is an important meningo-
coccal virulence factor. fHBP is a lipoprotein that is
expressed by over 97% of MnB strains [25] and can be
classified into two antigenically and immunologically
distinct subfamilies [26,27]. The first vaccine licensed
in the US (Trumenba1) [28] contains one lipidated fHBP
from each subfamily and was demonstrated in prospec-
tively designed licensure studies to provide broad cover-
age against MnB disease. The second vaccine (Bexsero1)
[29] contains a single and non lipidated fHBP variant from
subfamily B [30] and contains a Neisserial adhesin A
(NadA) and a porin A (PorA) that are restricted to a more
limited number of strains but may contribute to addition-
al coverage [31,32]. It will only be after these vaccines are
implemented into immunization schedules that their true
effectiveness can be assessed.
Another achievement in the 21st century is the develop-
ment and deployment of MenAfriVacTM. This is a me-
ningococcal serogroup A glycoconjugate vaccine, with the
goal to eradicate serogroup A meningococcal disease from
sub-Saharan Africa. Disease rates in this region, described
as the ‘meningitis belt’, were as high as 120 cases per
100k/p [33]. The development of MenAfriVac was based
on a successful collaboration between public and private
groups including CBER, and since 2010, more than
217 million doses have been delivered [34,35]. Since
introduction, disease rates have plummeted, with some
vaccinated areas reporting incidence as low as 2.5 per
100k/p [34] and thus MenAfriVac is another example of
the public health value of vaccines.
Advances have also been made in reducing the burden of
viral diseases, by introduction of vaccines against human
papilloma virus (HPV) and rotavirus. In 2006 Merck
licensed the first vaccine (Gardasil1) against HPV to
prevent genital warts, precancerous lesions and cervical
and other cancers caused by the HPV types covered by
the vaccine [36]. The vaccine is composed of four non-
infectious virus-like particles that are formed after ex-
pression of the major viral capsid protein in yeast [37].
The efficacy studies conducted with Gardasil1 in wom-
en, 15–26 years of age demonstrated exceptional efficacy
of 98% against persistent infection, external genital
lesions and cervical intraepithelial neoplasia by the tar-
geted serotypes. Recent post-licensure studies have dem-
onstrated a significant decrease in disease rates in the US
despite the relatively modest vaccine uptake rates of
57.3% and 34.6% in adolescent girls and boys respectively
[38]. A second vaccine, Cervarix1, a bivalent vaccine that
targets the cancer causing serotypes included in Garda-
sil1 (GSK), received US licensure in 2010 [39] In 2014 a
second generation vaccine from Merck, Gardasil-91 was
approved in the US. This adds additional protectionCurrent Opinion in Microbiology 2015, 27:96–102
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ing broad and more global coverage. In principle, with
optimal immunization rates, Gardasil-9 has the potential
to prevent approximately 90% of cancers caused by HPV
and, similar to Gardasil, >90% of genital warts [40].
While HPV can cause cervical cancer, rotavirus causes
severe, dehydrating diarrhea in children under five years
of age. Rotavirus gastroenteritis (RVGE) is a leading
cause of infant hospitalizations and deaths in both indus-
trialized and resource deprived nations. In 2008 the WHO
estimated 86 deaths per 100k/p in children under 5 years
accounting for 5% of all child deaths [41]. Two vaccines
are currently available internationally (Rotateq1, Merck/
Sanofi-Pasteur; Rotarix1, GSK) [42–44] and have dem-
onstrated a remarkable efficacy reducing RVGE cases by
90% in nations where these vaccines have been imple-
mented in child immunization programs [45]. The further
development and implementation of these life-saving
vaccines was almost stalled when in 1999, Rotashield1
manufactured by Wyeth was withdrawn nine months
post-licensure due to potential safety concerns of a rare
intestinal disorder called intussusception in very young
infants (<3 months) [46]. To be able to document the
safety of the vaccines and obtain licensure of rotavirus
vaccines, manufacturers were required to conduct un-
precedentedly large safety studies (>60 000) prior to
market authorization, and good safety profiles were dem-
onstrated, allowing global implementation of these im-
portant vaccines [45]. The impact of these vaccines is
enormous; in Mexico, for example, implementation of
rotavirus vaccination has reduced the incidence of diar-
rheal deaths in children <5 by 40–50% [47].
Vaccines currently in development
Many devastating childhood diseases are now prevent-
able through vaccination, which is considered the most
important public health measure second only to the
provision of safe drinking water [48]. This achievement
has led to a change in focus from providing immunity
against infectious diseases for the larger population, to
targeting protective immunity for specific at-risk popula-
tions. Here, we describe two vaccines currently in devel-
opment focused on protection of high risk populations
threatened by Dengue virus and Ebola virus (EBOV)
infections, as well as vaccines directed toward individuals
with high risk of S. aureus and C. difficile disease.
Dengue virus causes an estimated 50 million infections
each year globally, resulting in 500 000 hospitalizations
due to Dengue hemorrhagic fever [49,50]. Dengue, a
mosquito-borne disease, is caused by one of four viral
serotypes and is prevalent in tropical and subtropical
climates and in some temperate areas within the US,
Europe, Africa and the Middle East [51]. Control of
epidemics has largely relied on vector control, however,
for most efficient control, a prophylactic vaccine is clearlyCurrent Opinion in Microbiology 2015, 27:96–102 needed [49]. A recent Phase 3 trial of a recombinant live,
attenuated tetravalent dengue vaccine (CYD-TDV,
Sanofi-Pasteur) conducted in healthy Latin American
and Mexican children demonstrated good efficacy
(60.8%) by per-protocol analysis. Furthermore, serotype
specific efficacy was high, reducing dengue-related hos-
pitalization by 80.3% [51]. The success of this trial,
coupled with the development of several other dengue
vaccines, suggests a solution to this devastating disease
will be available in the very near future.
The EBOV epidemic in West Africa was declared a public
health emergency of international concern in August
2014 [52]. Cases of EBOV are usually sporadic and
localized; however, in the recent West African epidemic,
the virus spread rapidly to large population centers and
the number of cases and deaths has surpassed all previous
outbreaks combined [53]. With almost 24 000 suspected
cases reported and with an average case fatality rate of
50%, the WHO has granted permission to expedite the
development of a prophylactic vaccine [54]. Three vac-
cines are currently in development; two use an adenovirus
vector to deliver the Ebola glycoprotein (cAd3-EBO,
GSK and Ad26.ZEBOV/Mva-BN-Filo, J&J) while the
other utilizes an attenuated vesicular stomatitis virus
platform (VSV) platform (rVSV-ZEBOV, Merck) [55].
A Phase 1 trial of the bivalent cAd3-EBO demonstrated
protective titer of glycoprotein Zaire-specific antibodies
[56]. These promising results provide a solid background
to produce a protective vaccine against EBOV.
While Dengue virus and EBOV vaccines have focused on
protection of large populations, the development of S.
aureus vaccines is focused on protection of the individual.
S. aureus is a major public health concern causing signifi-
cant morbidity and mortality in hospital-associated and
community settings. S. aureus surgical site infections carry
a particularly high mortality rate with survivors typically
requiring additional 13–17 days in the hospital, signifi-
cantly increasing costs and draining valuable healthcare
resources [57]. The diverse range of disease and rapid
accumulation of antibiotic resistance has led to a focus
on the development of an efficacious vaccine. Two vac-
cines, with reported clinical data, have used a multiantigen
approach containing S. aureus capsular polysaccharide con-
jugated to carrier proteins and various surface expressed
proteins (SA4Ag, Pfizer) [58] or detoxified toxins (GSK)
[59]. While vaccine induced responses cannot be compared
between the two candidate vaccines, both vaccines were
safe and immunogenic during Phase 1 trials and develop-
ment of the Pfizer vaccine is proceeding into a pivotal
efficacy study [58,59]. A third vaccine focusing on a protein
and toxin-based approach has been in development
(Novartis/GSK) but no human safety or immunogenicity
data have been reported [60]. The introduction of an
efficacious vaccine against S. aureus will dramatically
reduce the burden placed on healthcare institutions bywww.sciencedirect.com
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designed for the protection of individuals at risk.
In the early 2000s, hospitals began reporting dramatic
increases in severe C. difficile infection. These infections
were linked to high levels of antibiotic use disrupting the
intestinal flora, which provides the opportunity for the
spore-forming C. difficile organism to flourish and cause
toxin-mediated diarrhea and colitis. Two vaccines, both
composed of detoxified forms of the two major C. difficile
toxins (A and B) are currently in clinical trials [61–63].
Proof of concept studies with anti-toxin monoclonal anti-
bodies have demonstrated that a vaccine has the potential
for preventing this disease [64]. These developments
demonstrate the recent paradigm shift in vaccinology,
from designing vaccines to provide community and pop-
ulation protection to a more personalized medicine ap-
proach, offering vaccination to specific at risk individuals.
Vaccines with new paths forward
Advances in vaccine design, driven by a deeper understand-
ing of disease pathogenesis and what constitutes a protec-
tive immune response, and coupled with an evolution in
regulatory thinking and approaches, has enabled the devel-
opment of vaccines to protect the world’s most vulnerable
citizen: newborn babies. Neonates have immature immune
systems and thus are at increased risk of infection, disease
and death. Although some vaccines, such as those for
hepatitis B virus, are administered at or close to birth, for
most vaccines there is a gap of up to one year before
protective immunity can be elicited through direct immu-
nization of an infant. One means of bridging this gap in
neonatal immunity is by immunizing the pregnant mother,
which enables transfer of protective antibody to the fetus in
utero and to the newborn through maternal antibody. Im-
munization of pregnant women has traditionally been per-
ceived to be risky from a safety standpoint and to this day,
no vaccine has been formally licensed for use in pregnant
women. However, based on the exquisite safety profile of
existing vaccines such as Tdap and influenza vaccines that
have been used safely in millions of individuals and the
need to protect neonates from these life-threatening infec-
tions, the US Advisory Committee on Immunization Prac-
tices (ACIP) issued ‘Guidance on vaccination practices in
pregnant and breastfeeding women,’ clarifying the regula-
tory process for maternal immunization [65]. The CDC
subsequently recommended these vaccines for use in preg-
nant mothers for each pregnancy, as well as other vaccines
such as hepatitis B for use in pregnant women at risk of
infection [65]. Currently, pregnant women in the US are
recommended to receive both their seasonal influenza
immunization and Tdap (tetanus, diphtheria and acellular
pertussis). Importantly, the Tdap vaccine is recommended
not for the prevention of disease in the pregnant woman
herself, but instead is for the prevention of pertussis in her
newborn infant. Recent studies conducted to assess the
effectiveness of maternal immunization against influenzawww.sciencedirect.com have shown the important public health impact of such an
approach [66,67].
In utero, during and after birth, developing fetuses and
neonates are vulnerable to many more life-threatening/
altering infections in addition to influenza and pertussis.
Infections with group B streptococcus (Streptococcus aga-
lactiae) for example, cause neonatal sepsis and are ac-
quired during birth from a colonized mother. While
screening and intrapartum antibiotic prophylaxis have
somewhat reduced the infection rates, these measures
are not as practical in low resource countries where most
of these infections occur. Therefore, safe and effective
vaccines are the best measures to prevent these devastat-
ing diseases. Another example of an important pathogen
to cause devastating illnesses and death in neonates and
very young infants is respiratory syncytial virus (RSV),
which causes life-threatening pulmonary infections in
newborns and especially in premature infants. It has
become clear over the last few years that RSV infection
and disease in the very young infants may be best
addressed through maternal immunization. With the ad-
vent of appropriate recommendations and newly forged
regulatory pathways to anticipate development and licen-
sure of vaccines for maternal immunization, development
of vaccines against each of these pathogens appears now
feasible and is being actively pursued [68]. This repre-
sents a new strategy of immunizing not just to protect the
immunized individual, but also to protect specific at-risk
populations (babies in utero and neonates).
In addition to a changing regulatory environment, recent
technological advances have provided new hope in the
quest for a RSV vaccine. RSV vaccine development has
been hindered by the failure of RSV vaccine trials in the
1960s, where immunized children experienced more
severe disease, including two deaths, than unvaccinated
controls and multiple attempts of producing vaccines to
protect young infants have failed [69]. Antibodies direct-
ed against the fusion (F) protein have been shown to be
neutralizing. Indeed, the only therapy currently on the
market for infants at high risk of RSV disease consists of a
humanized neutralizing anti-F protein monoclonal anti-
body (palivizumab, Synagis1) [70]. The F viral glycopro-
tein, which facilitates fusion of the virion and host cell
membrane via a dramatic transition from a metastable
prefusion conformation to a postfusion state, is a target
of several potent neutralizing antibodies [71]. Significant
advances in structure-guided protein engineering has led
to the identification of an F protein variant with a more
stable prefusion conformation that is able to induce neu-
tralizing antibodies significantly more potent than Syna-
gis1 [72,73]. Prior F protein vaccines were based on the
postfusion form which was less immunogenic and mainly
elicited neutralizing antibodies that were not protective
[72]. These recent developments and findings have sparked
new interest in the development of an efficacious RSVCurrent Opinion in Microbiology 2015, 27:96–102
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with a RSV vaccine to protect newborns.
Vaccines with medical need but unclear paths forward
There are still many infectious diseases that could be
potentially targeted by vaccines but for which a clear
scientific path is not apparent. Vaccines against sexually
transmitted infections (STIs) are clear examples of where
some successes have been achieved but where challenges
still remain. The development and introduction of HPV
vaccines were fueled by the understanding of how to elicit
an appropriate immune response in the genital tract to
prevent infection and disease with this important pathogen
and the introduction of these vaccines opened the door to
the societal dialogue about and acceptance of a STI vaccine.
Despite these successes, most STIs remain a major unmet
medical need and continue to pose a significant develop-
mental challenge. Two important examples of these are
human immunodeficiency virus type 1 (HIV-1) and Chla-
mydia trachomatis infections, which remain the leading viral
and bacterial causes of vaccine-preventable STIs world-
wide.
An estimated 35 million people currently live with an HIV
infection and approximately 2 million new infections are
reported globally each year [74]. Current therapeutic regi-
mens have provided a substantial decrease in HIV-related
morbidity and mortality [75,76], though a prophylactic
vaccine would offer the greatest impact on HIV spread
[77]. Several challenges have impeded this effort such as
HIV’s ability to rapidly establish a latent reservoir of
infection via integration of its genetic material into the
host chromosome and its genetic plasticity and complexity
of major vaccine target antigens [78]. Because of the genetic
diversity of HIV, vaccine efforts have focused on develop-
ing a vaccine that elicits broadly neutralizing antibodies
[79] and effective cytotoxic T cell responses [80]. Thus far
only limited efficacy (31%) has been achieved with a
canarypox vector/protein prime-boost vaccine in a clinical
trial [81] while 121 vaccines (prophylactic and therapeutic)
have been or are currently in development [82]. It remains
to be seen if this large effort coupled with continued
technological advances will provide the understanding
and means to develop a HIV vaccine.
The WHO has estimated that approximately 100 million
C. trachomatis (CT) infections occur globally [83], more than
1.4 million of these infections are reported in the United
States alone [84]. In contrast to Neisseria gonorrhoeae (GC),
CT infections are largely asymptomatic in nature and
therefore go often unnoticed. Infection can lead to pelvic
inflammatory disease (PID) and chronic disease sequelae
such as chronic pelvic pain and infertility. Because of the
polymicrobial etiology of PID (CT and GC being major
reportable causes [85]), it is unclear what impact a CT
vaccine, if it could be successfully developed, might have
on the disease. Vaccine trials in the 1960s against the ocularCurrent Opinion in Microbiology 2015, 27:96–102 form of chlamydial infection using formalin-fixed whole
organism demonstrated  the ability to induce short-term
immunity and a reduced incidence of scarring in vacci-
nated children. Despite these successes, immunity was
serovar-specific and enhanced disease was observed in
some individuals. Therefore, a subunit vaccine approach
has since been a major focus [86]. Thus far no C. tracho-
matis STI vaccine has been in clinical trials, partially
because of a lack of a complete understanding of human
immune correlates of protection (T cell and/or antibody)
and partially because of the difficulties in producing
native antigens expressed by Chlamydia [87,88]. Signifi-
cant advances in the identification of C. trachomatis genes
associated with immunopathology and the ability to
genetically inactivate their function have provided more
promise to an attenuated whole organism vaccine ap-
proach [89].
Conclusion
In summary, the positive public health impact of prophy-
lactic vaccines remains medically undisputed. For vac-
cines that have been used for a while, the most pressing
issues that remain are their implementation and contin-
ued use in the poorest countries globally, particularly in
those that are ravaged by war and other political turmoil.
To achieve even better global coverage however, will
require the continued collaboration and strong commit-
ment of the public and private sector. It is also encourag-
ing that over the last few years, increases in scientific
knowledge, changes in recommendations and policy and
new regulatory pathways are now providing the founda-
tion to develop vaccines for use in pregnant women to
address important neonatal infections and diseases for
which other approaches have either failed or were previ-
ously not feasible. Finally, after more than 100 years in
developing and implementing vaccines to protect popu-
lations, a new class of vaccines is being developed that
have the potential to protect individuals or groups of
individuals at risk for certain infectious diseases.
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